Quest Diagnostics Incorporated (DGX) Stock Forecast
DGX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.94 / 5 from 17 analysts
- Price target
- $251.40 average of analyst targets
- Upside to target
- +7.0% from the latest close
- Next earnings
- October 22, 2026 EPS estimate $2.85
- 52-week range
- $173.49 – $247.45
DGX analyst ratings
17 analystsNumber of analysts at each rating.
DGX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DGX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.87 | $2.82 | $2.94 | $2.60 | +10.4% | 14 |
| Current fiscal year (2026) | $11.20 | $11.12 | $11.49 | $9.85 | +13.7% | 16 |
| Next fiscal year (2027) | $12.03 | $11.79 | $12.56 | $11.20 | +7.5% | 16 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DGX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $3.05B | $2.96B | $3.10B | +8.3% | 12 |
| Current fiscal year (2026) | $12.01B | $11.96B | $12.13B | +8.9% | 15 |
| Next fiscal year (2027) | $12.56B | $12.41B | $12.77B | +4.6% | 15 |
DGX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DGX revenue: reported and forecast
DGX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.80 | $2.86 | $2.86 | $2.86 | $2.87 | +2.4% | 1 up · 0 down |
| Current fiscal year (2026) | $10.77 | $11.19 | $11.19 | $11.19 | $11.20 | +3.9% | 2 up · 1 down |
| Next fiscal year (2027) | $11.67 | $12.06 | $12.06 | $12.05 | $12.03 | +3.1% | 2 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DGX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DGX beat in 12 of 12.
What analysts expect from DGX
17 analysts cover Quest Diagnostics; their consensus rating is buy (3.94 on a 1–5 scale, where 5 is a strong buy). The average price target is $251.40, 7.0% above the latest close of $235.00. Analysts expect earnings of $11.20 per share for 2026, +13.7% from a year earlier. For 2027 the average estimate is $12.03 per share on revenue of $12.6 billion. Quest Diagnostics beat the EPS estimate in 12 of the last 12 quarters.
Related: DGX income statement, DGX key metrics, DGX chart. See the DGX stock overview for the latest quote and news.
DGX forecast FAQ
What is Quest Diagnostics's price target?
The average analyst price target for Quest Diagnostics is $251.40, 7.0% above the latest close of $235.00.
Is Quest Diagnostics a buy, hold or sell?
Of 17 analysts covering Quest Diagnostics, 7 rate it a strong buy, 2 a buy, 8 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Quest Diagnostics's EPS forecast?
Analysts forecast $11.20 per share for 2026 (range $11.12 to $11.49); for 2027 the estimate is $12.03.
What is Quest Diagnostics's revenue forecast?
The average revenue estimate for 2026 is $12.0 billion, growth of 8.9%; for 2027 it is $12.6 billion.
When does Quest Diagnostics report earnings?
Quest Diagnostics is expected to report results for the quarter ending September 30, 2026 on October 22, 2026 before the market opens; the EPS estimate is $2.85.
Does Quest Diagnostics usually beat earnings estimates?
Quest Diagnostics reported EPS at or above the analyst estimate in 12 of the last 12 quarters.